# First-Line Treatment for HIV-2

> **NCT02150993** · PHASE2,PHASE3 · COMPLETED · sponsor: **ANRS, Emerging Infectious Diseases** · enrollment: 210 (actual)

## Conditions studied

- HIV-2 Infection

## Interventions

- **DRUG:** Tenofovir + Emtricitabine or Lamivudine + Zidovudine
- **DRUG:** Tenofovir + Emtricitabine or Lamivudine + Lopinavir/ritonavir
- **DRUG:** Tenofovir + Emtricitabine or Lamivudine + Raltegravir

## Key facts

- **NCT ID:** NCT02150993
- **Lead sponsor:** ANRS, Emerging Infectious Diseases
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-26
- **Primary completion:** 2019-05-15
- **Final completion:** 2019-05-15
- **Target enrollment:** 210 (ACTUAL)
- **Last updated:** 2019-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02150993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02150993, "First-Line Treatment for HIV-2". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02150993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*